Table 4.
Characteristic | KD mutation (N = 35) |
HD mutation (N= 44) |
P value* | |
---|---|---|---|---|
N (%) | N (%) | |||
Age | ||||
≤ 50 | 11 (31%) | 13 (30%) | ||
> 50 | 24 (69%) | 27 (61%) | 0.92 | |
Unknown | 0 (0%) | 4 (10%) | ||
Menopausal status | ||||
Pre | 10 (29%) | 8 (18%) | ||
Post | 11 (31%) | 15 (34%) | 0.39 | |
Unknown | 14 (40%) | 21 (47%) | ||
Race | ||||
Caucasian | 30 (86%) | 41 (93%) | ||
Black | 2 (6%) | 1 (2%) | ||
Asian/Pacific Islander | 0 (0%) | 0 (0%) | 0.58 | |
Unknown or other | 3 (9%) | 2 (5%) | ||
Tumor size | ||||
0 –2 cm | 8 (23%) | 10 (23%) | ||
2.1 –5 cm | 9 (26%) | 10 (23%) | ||
> 5 cm | 2 (6%) | 1 (5%) | 0.9 | |
Unknown or NA | 16 (46%) | 23 (53%) | ||
Histologic subtype | ||||
Ductal | 32 (91%) | 40 (93%) | ||
Lobular | 2 (6%) | 2 (5%) | ||
Other | 1 (3%) | 1 (2%) | 1 | |
Grade | ||||
Low | 10 (29%) | 7 (16%) | ||
Intermediate | 18 (51%) | 24 (55%) | ||
High | 7 (20%) | 12 (27%) | 0.39 | |
Unknown or NA | 0 (0%) | 1 (2%) | ||
Positive lymph nodes | ||||
0 | 16 (46%) | 16 (36%) | ||
1 –3 | 6 (17%) | 14 (32%) | ||
> 3 | 9 (26%) | 6 (14%) | 0.18 | |
Unknown or NA | 4 (11%) | 8 (18%) | ||
ER | ||||
Postive | 30 (86%) | 36 (82%) | ||
Negative | 3 (9%) | 5 (11%) | 0.73 | |
Unknown | 2 (6%) | 4 (9%) | ||
PR | ||||
Positive | 29 (83%) | 27 (61%) | ||
Negative | 4 (11%) | 13 (30%) | 0.04 | |
Unknown | 2 (6%) | 4 (9%) | ||
HER2 | ||||
Positive | 2 (6%) | 4 (9%) | ||
Negative | 31 (89%) | 31 (70%) | 0.133 | |
Unknown | 2 (6%) | 9 (20%) | ||
Receptor status | ||||
ER+ or PR+/HER2− | 30 (86%) | 26 (59%) | ||
ER+ or PR+/HER2+ | 0 (0%) | 3 (7%) | ||
ER−and PR−/HER2+ | 2 (6%) | 0 (0%) | ||
ER−and PR−/HER2− | 1 (3%) | 5 (11%) | ||
Other | 2 (6%) | 10 (23%) | 0.008 | |
Recurrent disease | ||||
yes | 22 (63%) | 39 (89%) | ||
no | 12 (37%) | 5 (11%) | 0.007 | |
Metastatic at diagnosis | ||||
yes | 6 (17%) | 9 (20%) | ||
no | 29 (83%) | 35 (80%) | 0.71 | |
Unknown | 0 (0%) | 0 (0%) |
Note: "Unknown," "other," or "NA" not included in p value calculation.
KD = kinase domain, HD = helical domain